This filing is a scientific literature review, not a catalyst event. Monitor upcoming clinical data readouts for Piclidenoson in the Phase 3 psoriasis study and Namodenoson in Phase 3 HCC for near-term stock-moving catalysts — the 20-F annual report (filed March 2026) showed reliance on additional capital, so cash runway updates are also key.
Price Chart
Executive Summary
Can-Fite announced the publication of a peer-reviewed scientific article in Biomolecules Journal reviewing the therapeutic potential of its A3AR agonists Piclidenoson and Namodenoson across multiple disease areas. The publication summarizes findings from independent academic research groups but does not contain new clinical data, regulatory milestones, or financial information — it is a scientific literature review providing external validation of the platform technology.
Key Facts
- Peer-reviewed article published in Biomolecules Journal on June 22, 2026
- Article reviews A3AR agonist activity across solid tumors, MASH/liver fibrosis, autoimmune/inflammatory, osteoarthritis, neurodegenerative, obesity/metabolic, and rare genetic diseases
- No new clinical trial results, regulatory approvals, financial data, or guidance changes were announced
- Pipeline status unchanged: Namodenoson in Phase 3 HCC, Phase 2 pancreatic, Phase 2b MASH; Piclidenoson in pivotal Phase 3 psoriasis; CF602 for erectile dysfunction
- Over 1,600 patients treated in clinical studies to date
Financial Impact
No financial impact — the filing is a scientific publication announcement without new data, funding, or commercial milestones
Risk Factors
- Sub-$10M market cap micro-cap with history of losses and need for additional capital, as disclosed in the 2025 20-F
- No new financial or clinical data — publication alone is unlikely to materially shift valuation
- Forward-looking statements caution that actual results may differ materially
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-070365 |
| Document: ea0295423-6k_canfite.htm | 0001213900-26-070365 |
| Document: 0001213900-26-070365-index-headers.html | 0001213900-26-070365 |
| Document: 0001213900-26-070365-index.html | 0001213900-26-070365 |
| Document: 0001213900-26-070365.txt | 0001213900-26-070365 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.72 | awaiting T+5 | — | $1.65 (−4.07%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.26%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.66%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.79%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+30.08%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers